Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Salk scientists identify protein BCL6 as a key regulator of muscle maintenance in mice; BCL6-enhancing therapies may prevent ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

Beyond GLP-1 drugs, healthcare companies are expanding their portfolios with new cancer therapies ... who can’t diet or ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...

The FDA has approved Eli Lilly’s Omvoh (mirikizumab-mrkz ... According to the company, Omvoh is the first biologic drug in over 15 years to provide the FDA with two-year Phase III efficacy data at ...

Visible healing of the intestinal lining was observed in 46% of subjects treated with the therapy. Credit: SewCreamStudio/Shutterstock. Eli Lilly has received ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn's disease, an inflammatory bowel disease that causes chronic abdominal pain.

as did Eli Lilly, the maker of Mounjaro. As those developments continue to bubble away in the background, a new market is rapidly expanding. Late last year saw an onslaught of “natural ...